Clinical Scorecard: Creation and assessment of a predictive model for psychological distress in differentiated thyroid cancer patients receiving ¹³¹I treatment

At a Glance

Key Highlights

• Developed a predictive model for psychological distress in DTC patients receiving ¹³¹I therapy.
• Identified independent risk factors: poor sleep quality, TSH stimulation, pulmonary metastasis, social support, radiation exposure concerns, and low serum 25-hydroxyvitamin D levels.
• Achieved an AUC of 0.835 for model performance with good calibration and clinical utility.
• High prevalence of anxiety and depression in DTC patients receiving ¹³¹I therapy (38.7% to 52.5%).
• Model requires external validation in larger, multicenter cohorts.

Guideline-Based Recommendations

Diagnosis

• Use the developed nomogram to identify patients at risk for psychological distress.

Management

• Consider early interventions for patients identified as high-risk for psychological distress.

Monitoring & Follow-up

• Regularly assess psychological well-being in DTC patients undergoing ¹³¹I therapy.

Risks

• Monitor for anxiety and depression, which may impair quality of life and treatment adherence.

Patient & Prescribing Data

Patients diagnosed with differentiated thyroid cancer receiving ¹³¹I therapy.

Psychosocial stressors associated with ¹³¹I therapy necessitate attention to psychological health.

Clinical Best Practices

• Integrate psychological assessment into routine care for DTC patients.
• Utilize the predictive model to tailor support and interventions.

Related Resources & Content

• Study on psychological distress in DTC patients